Status:

TERMINATED

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Lead Sponsor:

FibroGen

Conditions:

Liver Fibrosis Due to Chronic Hepatitis B Infection

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The overall goal of this trial is to evaluate the efficacy of FG-3019 for reversing liver fibrosis in subjects with chronic hepatitis B infection who are beginning antiviral therapy with entecavir. Th...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Signed informed consent
  • Age of 18 to 75 years, inclusive
  • HBsAg positive for ≥24 weeks prior to screening
  • Liver fibrosis, confirmed by biopsy and histology
  • Willing to use contraception
  • Exclusion Criteria:
  • Female subjects who are pregnant or nursing
  • Prior antiviral therapy, with the exception of interferon therapy \>6 months prior to Day 1
  • Severe heart failure
  • Present hepatocellular carcinoma and history of other cancers
  • Severe anemia
  • Advanced kidney disease
  • Immunosuppressive therapy within 24 weeks prior to screening
  • Alcohol or drug abuse within the 12 months prior to screening
  • Trauma or surgical procedures requiring hospitalization within 8 weeks prior to Day 1
  • Planned elective surgery during the study including 9 weeks following the final dose of study drug
  • History of allergy against nucleoside analogs or human, humanized, chimeric, or murine monoclonal antibodies
  • Inability to cooperate with study personnel or a history of noncompliance to the medical regimen (i.e., subjects who would be expected to comply poorly with the treatment)
  • Clinically significant medical or psychiatric condition considered a high risk for participation in an investigational study
  • Morbid obesity (body mass index \[BMI\] \>40)
  • Inadequate IV access

Exclusion

    Key Trial Info

    Start Date :

    August 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2015

    Estimated Enrollment :

    114 Patients enrolled

    Trial Details

    Trial ID

    NCT01217632

    Start Date

    August 1 2010

    End Date

    June 1 2015

    Last Update

    August 16 2016

    Active Locations (9)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (9 locations)

    1

    Queen Mary Hospital

    Pokfulam, Hong Kong Island, Hong Kong

    2

    Ruttonjee Hospital

    Wan Chai, Hong Kong Island, Hong Kong

    3

    Princess Margaret Hospital

    Kowloon, Kowloon, Hong Kong

    4

    Prince of Wales Hospital

    Shatin, Kowloon, Hong Kong